Preliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (brevity).
Gibb, Adam Pirrie, S Paterson, K Davies, A Collins, G Menne,T McKay, P Fields, P Miall, F
Gibb, Adam
Pirrie, S
Paterson, K
Davies, A
Collins, G
Menne,T
McKay, P
Fields, P
Miall, F
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Preliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin Lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (brevity). 2016, 101:20 Haematologica